Skip to content
Inscripta, Inc.  logo — The Digital Genome Engineering Company

Inscripta, Inc.

The Digital Genome Engineering Company

Founded 2015 United States Pleasanton, United States 75 employees Series E Total: $459.00M

General Information

Company Name Inscripta, Inc.
Founded Year 2015
Location United States Pleasanton, United States
Founders / Decision Makers
Team member
Employees 75
Funding Stage Series E
Business Model B2B, D2C, API
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Inscripta, Inc. . To contact Inscripta, Inc. , visit inscripta.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Inscripta, Inc. compare?

A PDF of Inscripta, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Inscripta, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Inscripta, Inc.

Inscripta, Inc., known as "The Digital Genome Engineering Company," stands as a beacon in the field of genome engineering. Founded in 2015, the company is headquartered in the United States and aims to revolutionize biomanufacturing with innovative technologies that support a cleaner, healthier, and sustainable world.

As a leader in the life sciences technology sector, Inscripta has made significant strides in the bioeconomy, offering critical technologies that facilitate new biotech innovations globally. Their facilities in Pleasanton and Burlingame, California, underscore their commitment to expanding and bolstering domestic biomanufacturing capabilities.

The company's last significant investment was a $150.00M Series E round in April 2021, featuring a high-caliber roster of investors including D1 Capital Partners, T. Rowe Price, Durable Capital Partners, Foresite Capital, Morgan Stanley, Fidelity Investments, and JS Capital Management. This strong backing underscores investor confidence in Inscripta's potential to drive substantial advancements in genome engineering.

Business keywords: Digital Genome Engineering, Biomanufacturing, Genome Engineering, CRISPR, MAD7 CRISPR Nuclease, Synthetic Biology, Gene Editing, Single-Cell Genomics, Biotech Innovation, Automated Genome Editing, Benchtop Genome Editing Platform, Single Cell Writing, Bioeconomy, Trackable Editing, Collaborative Research and Development

Services & Products

Scaling biology
Developing bioalternatives
Replacing fossil-based ingredients and materials

Target Customers

Companies seeking sustainable supply chain solutions Industries looking for biomanufacturing options Organizations interested in bioalternative materials

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Series E $150.00M 7
D1 Capital Partners, T. Rowe Price +5
01 Apr 2021
Series D $50.00M -
01 Nov 2020
Series D $125.00M 4
Oak HC/FT, Venrock +2
01 Dec 2019
Series C $20.00M 4
Venrock, Paladin Capital Group +2
01 Apr 2019
Series C $30.00M 4
Venrock, Paladin Capital Group +2
01 Dec 2018
Series C $55.00M 2
Paladin Capital Group, Mérieux Equity Partners
01 Feb 2018
Series B $23.00M 1
Venrock
01 Feb 2017
Series A $6.00M -
01 Jan 2016

Inscripta, Inc. Alternatives & Competitors

View All Alternatives
Inscripta, Inc. vs
Namocell
Namocell United States

The Fastest Way to Single Cells

Series A
8 employees
Biotechnology, Life Sciences
Inscripta, Inc. vs
GenScript
GenScript United States

Scripting Possibilities - Make People and Nature Healthier through Biotechnology

IPO
1390 employees
Biotechnology
Inscripta, Inc. vs

Integra Therapeutics is a biotech company engineering the next generation of gene writing tools to c...

Seed
25 employees
Biotechnology, Health Care

FAQ About Inscripta, Inc.

The Digital Genome Engineering Company
Inscripta, Inc. was founded in 2015.
Inscripta, Inc. is headquartered in Pleasanton, United States.
Inscripta, Inc. has a B2B, D2C and API business model. Its revenue comes from Licensing, Product Sales and Service Fee.
Inscripta, Inc. has approximately 75 employees.
Inscripta, Inc. has completed 8 funding rounds, raising a total of $459.00M. The latest funding stage is Series E.
Inscripta, Inc. offers: Scaling biology, Developing bioalternatives, Replacing fossil-based ingredients and materials.
Top alternatives and competitors to Inscripta, Inc. include Namocell, GenScript, Integra Therapeutics, Logomix, Synthego. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Inscripta, Inc. and Namocell are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Inscripta, Inc. , https://bouncewatch.com/company/inscripta-inc, updated 16 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout